ClinicalTrials.gg
RecruitingNCT06040957Updated Feb 20, 2026

Bone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis

An interventional study of Bone marrow aspirate concentrate injection and intra-articular injection of Minimally manipulated adipose tissue in Knee Osteoarthritis, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.

Planned enrollment
Largest of 25
204 · median 50
Started
2024
with 2 others
No phase
21 of 31
11 open now
Primary completion
2027-01
later than 8 of 12 live
Registered
19th of 31
by date

Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 21 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 19th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, or all of them as a file.
02

Study summary

The MAST-GR study is a randomized controlled interventional trial with parallel treatment arms and 1:1 allocation

The primary objective of the study is to compare the safety and efficacy of a single intra-articular infiltration of Bone marrow aspirate concentrate (BMAC) with one of minimally manipulated adipose tissue (MM-AT) so as to determine the most effective cellular product in treating patients with knee osteoarthritis (OA).

The secondary objective is to demonstrate whether intra-articular infiltration of BMAC or MM-AT can induce disease-modifying effects in knee OA by imaging and biological assessments on peripheral blood.

The tertiary objective of the study is to identify factors that influence the clinical response to treatment (baseline characteristics of patients, biological characteristics of the treated knee, characteristics of cellular products, BMAC and MM-AT).

Read the detailed description

Patients with symptomatic unilateral knee OA will be included in a randomized controlled Trial (RCT), in which one group of patients will be treated with 1 intra-articular infiltration of BMAC, and one group will be treated with 1 intra-articular infiltration of MM-AT. A total of 204 patients will be included and will undergo infiltrative treatment after collecting informed consent for study participation and master data. Patients will be clinically evaluated at 0-2-6-12 months follow-up. Possible disease-modifying effects of the two cell products will be investigated by analysis on peripheral blood at 0-2-6-12 months follow-up and by evaluation of radiographic and magnetic resonance imaging (MRI) at 0 and 12 months follow-up. In addition, characterization of the portion of BMAC and MM-AT remaining from treatment will be carried out, as well as baseline assessment of peripheral blood on all patients, and synovial fluid and synovial membrane, where possible, to analyze their influence on clinical outcome.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • bone marrow aspirate concentrate
  • minimally manipulated adipose tissue
  • BMAC
  • MM-AT
  • intra-articular injection
  • knee injection
  • mesenchymal stromal cells
  • Randomized controlled trial
  • cellular orthobiological products
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with symptomatic unilateral knee OA with:

  1. Men or women aged 40 to 75 years;
  2. Signs and symptoms of OA with a clinical history of gonalgia or swelling for at least 6 months;
  3. Radiographic signs of OA (Kellgren-Lawrence grade 1-4);
  4. No benefit after at least 4 months of conservative treatment;
  5. Ability and consent of patients to actively participate in clinical and radiological (rx and MRI) follow-up;
  6. Signing of .

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to express consent;
  2. Patients aged \< to 40 and > to 75 years;
  3. Patients with axial deviations > 5°;
  4. Patients who have suffered trauma or undergone intra-articular infiltration of other substance in the previous 6 months;
  5. Patients who have undergone knee surgery in the previous 12 months;
  6. Patients with concomitant knee injuries causing joint pain or swelling (-focal full-thickness osteochondral defects, acute meniscal injuries);
  7. Patients with malignant neoplasms;
  8. Patients with uncompensated systemic diseases (rheumatic diseases, metabolic disorders such as diabetes and thyroid diseases);
  9. Patients with infectious diseases;
  10. Patients with histories of alcohol or drug abuse;
  11. Patients who are pregnant;
  12. Patients with allergies to anesthetics used in the procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    single intra-articular injection of BMAC

    Patients randomized in this group will undergo single knee intra-articular injection of bone marrow aspirate concentrate (BMAC)

    Biological: Bone marrow aspirate concentrate injection

  • Experimental
    single intra-articular injection of MM-AT

    Patients randomized in this group will undergo single knee intra-articular injection of minimally manipulated adipose tissue (MM-AT)

    Biological: intra-articular injection of Minimally manipulated adipose tissue

Interventions

  • BiologicalBone marrow aspirate concentrate injection

    single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest

  • Biologicalintra-articular injection of Minimally manipulated adipose tissue

    single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue

06

What researchers measure

Primary outcomes

  1. Western Ontario and McMaster University Osteoarthritis index (WOMAC) - Pain subscale

    It is a pathology-specific questionnaire used for the assessment of referred pain at the knee joint level in patients with OA

    Time frame: 6 months follow-up

Secondary outcomes

  1. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient. It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  2. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines the following categories: symptoms, stiffness, pain, daily activities, sports and quality of life

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  3. Visual Analogue Scale (VAS)

    Visual analog scale consisting of a straight line segment (10 cm length), the ends of which correspond to "no pain" (0) and "the strongest pain imaginable" (10).

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  4. EuroQol Visual Analogue Scale (EQ-VAS)

    EQ-VAS is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition).

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  5. Tegner Activity Level Scale

    Tegner Activity Level Scale is a questionnaire to find out the patient's level of physical activity.All patients will indicate the type of sporting activity performed and its frequency.

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  6. Objective parameters- Range of Motion

    Evaluation of the Range of Motion for comparative analysis.

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  7. Objective parameters - Circumferences

    Bilateral trans- and supra- patellar circumferences measurement for comparative analysis

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  8. Patient Acceptable Symptom State (PASS)

    A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no.

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  9. Minimally Clinical Important Difference (MCID)

    The patient should indicate the degree of perceived improvement after the infiltrative procedure.

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

  10. Expectations about the effectiveness of the treatment

    The patient should indicate at baseline what clinical benefits he or she expects from the treatment according to the question, "What benefits do you expect to get as a result of the treatment you will undergo?" the patient can choose from one of the following items:Full recovery, Definitely better, Much better, Slightly better,No change

    Time frame: baseline

  11. Kellgren-Lawrence score

    The Kellgren Lawrence scale classifies knee OA into 4 grades of subsequent greater severity, the parameters used being reduced joint space and the presence of osteophytes

    Time frame: baseline, 12 months follow-up

  12. 3 Tesla Nuclear Magnetic Resonance Imaging (3T MRI)

    Sequences such as T2-weighted FSE, FS-3D SPGR, and T2 Mapping will be used to assess cartilage thickness and signal, the presence of cysts and subchondral edema, joint profile, the presence of osteophytes and their size, the status of the menisci, both medial and lateral, and the status of the synovium.

    Time frame: baseline, 12 months follow-up

  13. Analysis of circulating micro RNAs

    miRNAs, involved in OA progression, will be identified and quantified, including miR675-5p, miR-31-5p and miR-33a-5p

    Time frame: baseline, 2 months, 6 months, 12 months follow-up

07

Study locations

1 of 1 sites recruiting
  • Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
    Recruiting
    • Luca Andriolo, MD · Contactluca.andriolo@ior.it · 6366567
    • Roberta Licciardi, MSc · Contactroberta.licciardi@ior.it · 6366567
    • Francesca Veronesi, PhD · Sub investigator
    • Alessandro Di Martino, MD · Sub investigator
    • Angelo Boffa, MD · Sub investigator
    • Stefano Zaffagnini, MD · Sub investigator
    • Marco Franceschini, MD · Sub investigator
    • Iacopo Romandini, MD · Sub investigator
    • Gianluca Giavaresi, MD · Sub investigator
    • Viviana Costa, PhD · Sub investigator
    • Deyanira Contartese, PhD · Sub investigator
    • Silvia Brogini, PhD · Sub investigator
    • Melania Maglio, PhD · Sub investigator
    • Veronica Borsari, PhD · Sub investigator
    • Marco Miceli, MD · Sub investigator
    • Paolo Spinnato, MD · Sub investigator
08

References and documents

Publications

  • Anz AW, Hubbard R, Rendos NK, Everts PA, Andrews JR, Hackel JG. Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 1 Year: A Prospective, Randomized Trial. Orthop J Sports Med. 2020 Feb 18;8(2):2325967119900958. doi: 10.1177/2325967119900958. eCollection 2020 Feb. PubMed 32118081 ↗
  • Basile M, Rumi F, Palmeri M, Mattozzi I, Manzoli L, Mammucari M, Gigliotti S, Bernabei R, Cicchetti A. Il burden economico dell'inappropriatezza prescrittiva nella gestione dell'osteoartrite in Italia. Glob Reg Health Technol Assess. 2020 Dec 10;7:101-108. doi: 10.33393/grhta.2020.2130. eCollection 2020 Jan-Dec. Italian. PubMed 36627953 ↗
  • Boffa A, Merli G, Andriolo L, Lattermann C, Salzmann GM, Filardo G. Synovial Fluid Biomarkers in Knee Osteoarthritis: A Systematic Review and Quantitative Evaluation Using BIPEDs Criteria. Cartilage. 2021 Dec;13(1_suppl):82S-103S. doi: 10.1177/1947603520942941. Epub 2020 Jul 25. PubMed 32713185 ↗
  • Boffa A, Di Martino A, Andriolo L, De Filippis R, Poggi A, Kon E, Zaffagnini S, Filardo G. Bone marrow aspirate concentrate injections provide similar results versus viscosupplementation up to 24 months of follow-up in patients with symptomatic knee osteoarthritis. A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2022 Dec;30(12):3958-3967. doi: 10.1007/s00167-021-06793-4. Epub 2021 Nov 12. PubMed 34767030 ↗
  • Cai X, Yuan S, Zeng Y, Wang C, Yu N, Ding C. New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol. 2021 Apr 15;12:645842. doi: 10.3389/fphar.2021.645842. eCollection 2021. PubMed 33935742 ↗
  • Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011 Jul 8;9(1):11-5. doi: 10.1016/j.stem.2011.06.008. PubMed 21726829 ↗
  • Carelli S, Messaggio F, Canazza A, Hebda DM, Caremoli F, Latorre E, Grimoldi MG, Colli M, Bulfamante G, Tremolada C, Di Giulio AM, Gorio A. Characteristics and Properties of Mesenchymal Stem Cells Derived From Microfragmented Adipose Tissue. Cell Transplant. 2015;24(7):1233-52. doi: 10.3727/096368914X681603. Epub 2014 May 6. PubMed 24806078 ↗
  • Cavallo C, Boffa A, Andriolo L, Silva S, Grigolo B, Zaffagnini S, Filardo G. Bone marrow concentrate injections for the treatment of osteoarthritis: evidence from preclinical findings to the clinical application. Int Orthop. 2021 Feb;45(2):525-538. doi: 10.1007/s00264-020-04703-w. Epub 2020 Jul 13. PubMed 32661635 ↗
  • Costa V, Carina V, Conigliaro A, Raimondi L, De Luca A, Bellavia D, Salamanna F, Setti S, Alessandro R, Fini M, Giavaresi G. miR-31-5p Is a LIPUS-Mechanosensitive MicroRNA that Targets HIF-1alpha Signaling and Cytoskeletal Proteins. Int J Mol Sci. 2019 Mar 28;20(7):1569. doi: 10.3390/ijms20071569. PubMed 30925808 ↗
  • Costa V, Lo Dico A, Rizzo A, Rajata F, Tripodi M, Alessandro R, Conigliaro A. MiR-675-5p supports hypoxia induced epithelial to mesenchymal transition in colon cancer cells. Oncotarget. 2017 Apr 11;8(15):24292-24302. doi: 10.18632/oncotarget.14464. PubMed 28061476 ↗
  • Costa V, Carina V, Raimondi L, De Luca A, Bellavia D, Conigliaro A, Salamanna F, Alessandro R, Fini M, Giavaresi G. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation. Cells. 2019 Nov 22;8(12):1495. doi: 10.3390/cells8121495. PubMed 31771093 ↗
  • Costa V, Raimondi L, Conigliaro A, Salamanna F, Carina V, De Luca A, Bellavia D, Alessandro R, Fini M, Giavaresi G. Hypoxia-inducible factor 1Alpha may regulate the commitment of mesenchymal stromal cells toward angio-osteogenesis by mirna-675-5P. Cytotherapy. 2017 Dec;19(12):1412-1425. doi: 10.1016/j.jcyt.2017.09.007. Epub 2017 Oct 27. PubMed 29111380 ↗
  • Costa V, De Fine M, Carina V, Conigliaro A, Raimondi L, De Luca A, Bellavia D, Salamanna F, Alessandro R, Pignatti G, Fini M, Giavaresi G. How miR-31-5p and miR-33a-5p Regulates SP1/CX43 Expression in Osteoarthritis Disease: Preliminary Insights. Int J Mol Sci. 2021 Feb 28;22(5):2471. doi: 10.3390/ijms22052471. PubMed 33671114 ↗
  • Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, Maria O, Nabavi N, Manolson MF, Harrison RE, Dixon SJ, Sims SM, Mizianty MJ, Kurgan L, Haroun S, Boire G, de Fatima Lucena-Fernandes M, de Brum-Fernandes AJ. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study. Arthritis Rheum. 2013 Jan;65(1):148-58. doi: 10.1002/art.37722. PubMed 23044761 ↗
  • Filardo G, Perdisa F, Roffi A, Marcacci M, Kon E. Stem cells in articular cartilage regeneration. J Orthop Surg Res. 2016 Apr 12;11:42. doi: 10.1186/s13018-016-0378-x. PubMed 27072345 ↗
  • Filardo G, Tschon M, Perdisa F, Brogini S, Cavallo C, Desando G, Giavaresi G, Grigolo B, Martini L, Nicoli Aldini N, Roffi A, Fini M, Kon E. Micro-fragmentation is a valid alternative to cell expansion and enzymatic digestion of adipose tissue for the treatment of knee osteoarthritis: a comparative preclinical study. Knee Surg Sports Traumatol Arthrosc. 2022 Mar;30(3):773-781. doi: 10.1007/s00167-020-06373-y. Epub 2021 Jan 19. PubMed 33464397 ↗
  • Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. Am J Sports Med. 2020 Mar;48(3):588-598. doi: 10.1177/0363546519899923. PubMed 32109160 ↗
  • Giorgini A, Selleri F, Zambianchi F, Cataldo G, Francioni E, Catani F. Autologous micro-fragmented adipose tissue associated with arthroscopy in moderate-severe knee osteoarthritis: outcome at two year follow-up. BMC Musculoskelet Disord. 2022 Nov 8;23(1):963. doi: 10.1186/s12891-022-05921-6. PubMed 36348344 ↗
  • Goldring SR, Goldring MB. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk. Nat Rev Rheumatol. 2016 Nov;12(11):632-644. doi: 10.1038/nrrheum.2016.148. Epub 2016 Sep 22. PubMed 27652499 ↗
  • Hong Z, Chen J, Zhang S, Zhao C, Bi M, Chen X, Bi Q. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019 May;43(5):1123-1134. doi: 10.1007/s00264-018-4099-0. Epub 2018 Aug 14. PubMed 30109404 ↗
  • Iyyanki T, Hubenak J, Liu J, Chang EI, Beahm EK, Zhang Q. Harvesting technique affects adipose-derived stem cell yield. Aesthet Surg J. 2015 May;35(4):467-76. doi: 10.1093/asj/sju055. Epub 2015 Mar 18. PubMed 25791999 ↗
  • Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review of the Evidence. J Bone Joint Surg Am. 2015 Dec 16;97(24):2047-60. doi: 10.2106/JBJS.N.00743. PubMed 26677239 ↗
  • Pagani S, Veronesi F, Giavaresi G, Filardo G, Papio T, Romandini I, Fini M. Autologous Protein Solution Effect on Chondrogenic Differentiation of Mesenchymal Stem Cells from Adipose Tissue and Bone Marrow in an Osteoarthritic Environment. Cartilage. 2021 Dec;13(2_suppl):225S-237S. doi: 10.1177/1947603521993217. Epub 2021 Feb 15. PubMed 33583216 ↗
  • Pagani S, Borsari V, Veronesi F, Ferrari A, Cepollaro S, Torricelli P, Filardo G, Fini M. Increased Chondrogenic Potential of Mesenchymal Cells From Adipose Tissue Versus Bone Marrow-Derived Cells in Osteoarthritic In Vitro Models. J Cell Physiol. 2017 Jun;232(6):1478-1488. doi: 10.1002/jcp.25651. Epub 2016 Oct 26. PubMed 27739057 ↗
  • Shanmugasundaram S, Vaish A, Chavada V, Murrell WD, Vaishya R. Assessment of safety and efficacy of intra-articular injection of stromal vascular fraction for the treatment of knee osteoarthritis-a systematic review. Int Orthop. 2021 Mar;45(3):615-625. doi: 10.1007/s00264-020-04926-x. Epub 2021 Jan 12. PubMed 33432400 ↗
  • Ulivi M, Meroni V, Vigano M, Colombini A, Lombardo MDM, Rossi N, Orlandini L, Messina C, Sconfienza LM, Peretti GM, Mangiavini L, de Girolamo L. Micro-fragmented adipose tissue (mFAT) associated with arthroscopic debridement provides functional improvement in knee osteoarthritis: a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2023 Aug;31(8):3079-3090. doi: 10.1007/s00167-022-07101-4. Epub 2022 Aug 30. PubMed 36040510 ↗
  • Anil U, Markus DH, Hurley ET, Manjunath AK, Alaia MJ, Campbell KA, Jazrawi LM, Strauss EJ. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee. 2021 Oct;32:173-182. doi: 10.1016/j.knee.2021.08.008. Epub 2021 Sep 6. PubMed 34500430 ↗
  • Veronesi F, Fini M, Martini L, Berardinelli P, Russo V, Filardo G, Di Matteo B, Marcacci M, Kon E. In Vivo Model of Osteoarthritis to Compare Allogenic Amniotic Epithelial Stem Cells and Autologous Adipose Derived Cells. Biology (Basel). 2022 Apr 28;11(5):681. doi: 10.3390/biology11050681. PubMed 35625409 ↗
  • Veronesi F, Cadossi M, Giavaresi G, Martini L, Setti S, Buda R, Giannini S, Fini M. Pulsed electromagnetic fields combined with a collagenous scaffold and bone marrow concentrate enhance osteochondral regeneration: an in vivo study. BMC Musculoskelet Disord. 2015 Sep 2;16:233. doi: 10.1186/s12891-015-0683-2. PubMed 26328626 ↗
  • Veronesi F, Salamanna F, Martini L, Fini M. Naturally Occurring Osteoarthritis Features and Treatments: Systematic Review on the Aged Guinea Pig Model. Int J Mol Sci. 2022 Jun 30;23(13):7309. doi: 10.3390/ijms23137309. PubMed 35806306 ↗
  • Veronesi F, Desando G, Fini M, Parrilli A, Lolli R, Maglio M, Martini L, Giavaresi G, Bartolotti I, Grigolo B, Sartori M. Bone marrow concentrate and expanded mesenchymal stromal cell surnatants as cell-free approaches for the treatment of osteochondral defects in a preclinical animal model. Int Orthop. 2019 Jan;43(1):25-34. doi: 10.1007/s00264-018-4202-6. Epub 2018 Oct 15. PubMed 30324310 ↗
  • Veronesi F, Berni M, Marchiori G, Cassiolas G, Muttini A, Barboni B, Martini L, Fini M, Lopomo NF, Marcacci M, Kon E. Evaluation of cartilage biomechanics and knee joint microenvironment after different cell-based treatments in a sheep model of early osteoarthritis. Int Orthop. 2021 Feb;45(2):427-435. doi: 10.1007/s00264-020-04701-y. Epub 2020 Jul 14. PubMed 32661637 ↗
  • Veronesi F, Giavaresi G, Tschon M, Borsari V, Nicoli Aldini N, Fini M. Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease. Stem Cells Dev. 2013 Jan 15;22(2):181-92. doi: 10.1089/scd.2012.0373. Epub 2012 Nov 16. PubMed 23030230 ↗
  • Veronesi F, Maglio M, Contartese D, Martini L, Muttini A, Fini M. Stromal Vascular Fraction and Amniotic Epithelial Cells: Preclinical and Clinical Relevance in Musculoskeletal Regenerative Medicine. Stem Cells Int. 2021 Feb 18;2021:6632052. doi: 10.1155/2021/6632052. eCollection 2021. PubMed 33688354 ↗
  • Andriolo L, Veronesi F, Zanasi L, Costa V, Franceschini M, Miceli M, Spinnato P, Zaffagnini S, Giavaresi G, Filardo G. Adipose tissue-derived versus bone marrow-derived cell concentrates for the injective treatment of knee osteoarthritis: protocol of a prospective randomised controlled trial. BMJ Open. 2025 Apr 30;15(4):e092379. doi: 10.1136/bmjopen-2024-092379. PubMed 40306987 ↗

Individual participant data

Plan to share: No — We will be able to share a subset of aggregated data, wich will not allow for the identification of participants

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 36 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Sep 18, 2023
StartActual
Jan 8, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06040957
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Jan 8, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Luca Andriolo, MD
Contact
luca.andriolo@ior.it
6366567 ext. 051
Roberta Licciardi, MSc
Contact
roberta.licciardi@ior.it
6366567 ext. 051
Luca Andriolo, MD
principal investigator · Istituto Ortopedico Rizzoli - II Clinica Ortopedica e Traumatologica

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion